Date: 7 June 2023 Your Name: Yue Hu Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023 Your Name: Tao Pan Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) No time limit for this item. | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nere |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023 Your Name: Xi Cai Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023

Your Name: Quan-Sheng He

Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023

Your Name: Yu-Bao Zheng

Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023

Your Name: Ming-Sheng Huang

Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Doumant as honoraria for | None |
|----|---|------|
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, | None |
| | | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending meetings and/or travel | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data | None |
| | Safety Monitoring Board or | |
| | Advisory Board | |
| 10 | Leadership or fiduciary role | None |
| | in other board, society, | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, | None |
| | materials, drugs, medical | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- | None |
| | financial interests | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023

Your Name: Zai-Bo Jiang

Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for | None |
|----|---|------|
| 5 | - | None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| | | |
| | | |
| 10 | Leadership or fiduciary role in other board, society, | None |
| | | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | None |
| | | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- financial interests | None |
| | | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023

Your Name: Jun-Wei Chen

Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | None | |
| | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for | None |
|----|---|------|
| 5 | - | None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| | | |
| | | |
| 10 | Leadership or fiduciary role in other board, society, | None |
| | | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | None |
| | | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- financial interests | None |
| | | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date: 7 June 2023 Your Name: Chun Wu Manuscript Title: Transarterial chemoembolization may improve survival in patients with unresectable hepatocellular carcinoma treated with a tyrosine kinase inhibitor and an immune checkpoint inhibitor Manuscript number (if known): No

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, | None | |
| | provision of study materials, medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | None | |
| | | | |
| | | | |
| 4 | Consulting fees | None | |
| | | | |

| 5 | Payment or honoraria for | None |
|----|---|------|
| 5 | - | None |
| | lectures, presentations, speakers bureaus, | |
| | manuscript writing or | |
| | educational events | |
| 6 | Payment for expert | None |
| 0 | | None |
| | testimony | |
| 7 | Current for otton ding | Nexe |
| / | Support for attending | None |
| | meetings and/or travel | |
| | | |
| | | |
| | | |
| 8 | Patents planned, issued or | None |
| | pending | |
| | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None |
| | | |
| | | |
| 10 | Leadership or fiduciary role in other board, society, | None |
| | | |
| | committee or advocacy | |
| | group, paid or unpaid | |
| 11 | Stock or stock options | None |
| | | |
| | | |
| 12 | Receipt of equipment, materials, drugs, medical | None |
| | | |
| | writing, gifts or other | |
| | services | |
| 13 | Other financial or non- financial interests | None |
| | | |
| | | |

I have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Please place an "X" next to the following statement to indicate your agreement: